BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33248478)

  • 1. Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.
    Bancos I; Atkinson E; Eng C; Young WF; Neumann HPH;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):13-21. PubMed ID: 33248478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal pheochromocytoma and childbirth in Sweden 1973-2015: a population-based study on short and long-term outcome.
    Gunnesson L; Ragnarsson O; Nilsson M; Sengpiel V; Elfvin A; Elias E; Muth A
    Endocrine; 2024 May; 84(2):720-726. PubMed ID: 38421555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome - a systematic review.
    Langton K; Tufton N; Akker S; Deinum J; Eisenhofer G; Timmers H; Spaanderman M; Lenders J
    BJOG; 2021 Jul; 128(8):1264-1272. PubMed ID: 33342020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraganglioma in Pregnancy: A Case Series and Review of the Literature.
    Wing LA; Conaglen JV; Meyer-Rochow GY; Elston MS
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3202-9. PubMed ID: 26083822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of maternal pheochromocytoma on the fetus and neonate.
    Iijima S
    Gynecol Endocrinol; 2019 Apr; 35(4):280-286. PubMed ID: 30614304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
    Park H; Kim MS; Lee J; Kim JH; Jeong BC; Lee S; Lee SK; Cho SY; Jin DK
    Front Endocrinol (Lausanne); 2020; 11():610746. PubMed ID: 33584544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pheochromocytoma and Paraganglioma in Pregnancy: a New Era.
    Gruber LM; Young WF; Bancos I
    Curr Cardiol Rep; 2021 May; 23(6):60. PubMed ID: 33961120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
    Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
    J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seizures in patients with a phaeochromocytoma/paraganglioma (PPGL): A review of clinical cases and postulated pathological mechanisms.
    Li Y; Zhang B
    Rev Neurol (Paris); 2019 Oct; 175(9):495-505. PubMed ID: 31133278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study.
    Ebbehoj A; Stochholm K; Jacobsen SF; Trolle C; Jepsen P; Robaczyk MG; Rasmussen ÅK; Feldt-Rasmussen U; Thomsen RW; Søndergaard E; Poulsen PL
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2251-e2261. PubMed ID: 33479747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phaeochromocytoma in pregnancy. Five cases and a review of the literature.
    Harper MA; Murnaghan GA; Kennedy L; Hadden DR; Atkinson AB
    Br J Obstet Gynaecol; 1989 May; 96(5):594-606. PubMed ID: 2667632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study.
    Zhao L; Meng X; Mei Q; Fan H; Liu Y; Zhou X; Zhu H; Zhang S
    Front Endocrinol (Lausanne); 2022; 13():877341. PubMed ID: 35721724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of Pheochromocytoma/Paraganglioma Screening in At-Risk Populations.
    Grigoryan S; Nhan W; Zhang L; Urban C; Zhao L; Turcu AF
    J Clin Endocrinol Metab; 2023 May; 108(6):e343-e349. PubMed ID: 36469797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnosis and management of pheochromocytoma and paraganglioma during pregnancy.
    Clifton-Bligh RJ
    Rev Endocr Metab Disord; 2023 Feb; 24(1):49-56. PubMed ID: 36637675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MANAGEMENT OF CATECHOLAMINE-SECRETING TUMORS IN PREGNANCY: A REVIEW.
    Prete A; Paragliola RM; Salvatori R; Corsello SM
    Endocr Pract; 2016 Mar; 22(3):357-70. PubMed ID: 26536138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
    Gagnon N; Mansour S; Bitton Y; Bourdeau I
    Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma.
    Giavarini A; Chedid A; Bobrie G; Plouin PF; Hagège A; Amar L
    Heart; 2013 Oct; 99(19):1438-44. PubMed ID: 23837998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phaeochromocytoma in black South Africans - a 30-year audit.
    Huddle KR
    S Afr Med J; 2011 Mar; 101(3):184-8. PubMed ID: 21382250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of phaeochromocytoma in pregnancy.
    Biggar MA; Lennard TW
    Br J Surg; 2013 Jan; 100(2):182-90. PubMed ID: 23180595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catecholamine-induced cardiomyopathy: an endocrinologist's perspective.
    Kumar A; Pappachan JM; Fernandez CJ
    Rev Cardiovasc Med; 2021 Dec; 22(4):1215-1228. PubMed ID: 34957765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.